Toward a new therapeutic backbone in myeloma

Abstract

The use of novel agents both singularly and in combination has transformed the treatment paradigm for patients with multiple myeloma. Now, the combination of bortezomib and thalidomide with the more traditional doublet of melphalan and prednisone has delivered a remarkably high response rate and favorable toxicity profile in patients with relapsed multiple myeloma.